Journal
CHEST
Volume 143, Issue 2, Pages 398-405Publisher
ELSEVIER
DOI: 10.1378/chest.12-1372
Keywords
-
Categories
Funding
- INSERM (French National Institutes of Health and Medical Research)
- Novartis Pharma SAS
- LA-SEE
- AstraZeneca
- Pfizer, Inc
- Takeda Pharmaceuticals International GmbH
- Actelion Pharmaceuticals Ltd
- Aerocrine
- Bayer AG
- Chiesi Farmaceutici SpA
- GlaxoSmithKline plc
- Eli Lilly and Company
- Merck Co, Inc
- Mundipharma International
- Stallergenes S.A.
- Teva Pharmaceuticals Industries, Ltd
- United Therapeutics Corporation
- Merck Sharp Dohme Corp
- Sanofi (formerly named Sanofi-Aventis)
- LA-SER
Ask authors/readers for more resources
Background: Omalizumab has been shown to decrease the risk of hospitalization or ED visits in patients with uncontrolled severe allergic asthma compared with placebo. This longitudinal study observed the conditions under which omalizumab is prescribed in real-life settings and assessed whether its use as an add-on therapy alongside standard treatments decreases the risk of severe asthmatic exacerbations. Methods: A cohort of adult patients with uncontrolled severe asthma despite optimal treatment with inhaled and oral corticosteroids and a long-acting beta(2)-agonist but no treatment with omalizumab upon entry was assembled. Risk of hospitalization or ED visits for asthma exacerbation was assessed using the Andersen-Gill extension of the Cox model for repeated events, controlling for age, sex, smoking history, BMI, gastroesophageal reflux, allergic status, allergic rhinitis, treatment, and hospitalization or ED visits for asthma in the 2 months prior to omalizumab treatment. Results: Overall, 163 physicians recruited 767 patients, of whom 374 took omalizumab at least once (mean observation period, 20.4 months). Omalizumab use was associated with an adjusted relative risk of 0.57 (95% CI, 0.43-0.78) for hospitalization or ED visits for asthma. In users of omalizumab, the adjusted relative risk of hospitalization or ED visits for asthma during omalizumab treatment vs nontreatment periods was 0.40 (95% CI, 0.28-0.58). Conclusions: Add-on omalizumab is associated with a significantly decreased risk of hospitalization or ED visits in patients with uncontrolled severe asthma in real-life practice. CHEST 2013; 143(2):398-405
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available